



16 July 2018

VIA E-MAIL ONLY

James Love
Knowledge Ecology International
1621 Connecticut Ave. NW, Suite 500
Washington, DC 20009

IN RE: Prospective Grant of an Exclusive License (NIH License Application A-257-2018) to Morphix Biotherapeutics, published on 15 May 2018 in *Federal Register* Vol. 83, No. 94, page 22501.

Dear Mr. Love:


Thank you for providing us with your comments in an email dated May 31, 2018 regarding the notice of the proposed license to Morphix Biotherapeutics (Morphix) by the National Cancer Institute (NCI).

Prior to posting a notice for a proposed grant of an exclusive license, the NCI reviewed the company's business development plan and other available information and determined that the criteria set forth in 37 CFR 404.7(a)(1)(ii-iii) have been satisfied and that the company is qualified both technically and financially to be granted an exclusive license to the Government's intellectual property in the fields of use as specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license.

Your comments have been given full consideration, but we have not found them to be persuasive. You stated in your email that the company does not have a website and that there is little public information about it. This is incorrect. An Internet search will return their facebook page <https://www.facebook.com/morphix/> and their linkedin page <https://www.linkedin.com/company/morphix/>, which refers to their website www.morphix.com, which describes the company. We are not able to provide business confidential information from their business plan. Further, with regard to your comments about transparency, your organization is welcome to submit requests for documents; such requests should be filed under the Freedom of Information Act. The webpage for the NIH FOIA Office provides more information on filing requests: www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office/submitting-foia-requests. Note that under 35 USC sec 209, the business development plan submitted by a prospective licensee "shall be treated by the Federal agency as commercial and financial information obtained from a person and privileged and confidential and not subject to disclosure under section 552 of title 5."

In conclusion, NCI has determined that your objection did not raise an issue that would preclude the grant of the proposed exclusive license, and the NCI intends to proceed with the negotiation of the proposed exclusive license, the terms of which have not yet been negotiated. All of the regulations and statutes governing the grant of an exclusive license have been adhered to during the evaluation of the Morphix license application.

Sincerely,



Jaime M. Greene, M.S.
Senior Technology Transfer Manager
National Cancer Institute, TTC
greenejaime@mail.nih.gov